Story perspectives

Ginkgo Bioworks Boosts AI in Drug Discovery with Partnerships

9/12/2025

Summary

Story summary

Ginkgo Bioworks launched initiatives to enhance AI in biologics drug discovery, partnering with Apheris for the Antibody Developability Consortium and the AbDev AI Competition to improve antibody property predictions.
The consortium will leverage Ginkgo's AI and Apheris' federated computing to create high-quality datasets, with initial results expected in 2026.
Insitro partnered with Eli Lilly to develop machine learning models for predicting small molecule pharmacological properties, aiming to streamline drug design using Lilly's preclinical data.
The AbDev AI Competition, running until early November, offers $60,000 in prizes to promote advancements in antibody AI modeling.

History

Historical Context

The FDA's approval of Zarxio in 2015 marked a pivotal moment in biologics regulation, allowing companies like Ginkgo Bioworks to innovate in drug discovery. This shift reflects a broader trend of integrating artificial intelligence into biotechnology, enhancing the efficiency of drug development and potentially improving patient outcomes as the industry adapts to new technological advancements.

1 of 2

Story summary

Ginkgo Bioworks launched initiatives to enhance AI in biologics drug discovery, partnering with Apheris for the Antibody Developability Consortium and the AbDev AI Competition to improve antibody property predictions.
The consortium will leverage Ginkgo's AI and Apheris' federated computing to create high-quality datasets, with initial results expected in 2026.
Insitro partnered with Eli Lilly to develop machine learning models for predicting small molecule pharmacological properties, aiming to streamline drug design using Lilly's preclinical data.
The AbDev AI Competition, running until early November, offers $60,000 in prizes to promote advancements in antibody AI modeling.

1 / 2